Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Riboflavin dosing regimens safely improve visual acuity in keratoconus, corneal ectasia

12 Apr 2018
The cornea, the transparent outermost layer of the eye, protects the eye from infection and physical injury.

Both the 2- and 5-minute riboflavin dosing regimens are safe and confer similar reduction in the maximum keratometry value in patients with keratoconus or corneal ectasia, reports a new study.

The mean reductions in maximum keratometry from baseline were 0.97 and 0.76 dioptres with 2- and 5-minute riboflavin dosing intervals at 6 months, respectively (90 percent CI for treatment difference, –0.23 to 0.66; per-protocol population).

At 6 months, both dosing intervals led to a mean improvement in corrected distance visual acuity (CDVA) of 0.07 logarithm of the minimum angle of resolution or 3.5 letters. Of the 635 study and fellow eyes examined at 6 months, 134 (21 percent) gained and 32 (5 percent) lost two or more lines of CDVA.

Three eyes (0.4 percent) developed sterile infiltrates, three (0.4 percent) had recurrent epithelial defects, and one (0.1 percent) had delayed epithelial healing with dendrites. Retreatment was performed in three eyes (0.4 percent).

A total of 510 patients with progressive keratoconus or ectasia after refractive surgery were included in this prospective, randomized, single-centre equivalence trial. One eye per patients was randomly assigned to 2- or 5- minute riboflavin dosing intervals with standard corneal crosslinking (epithelial removal and 30-minute irradiation with 3 mW/cm2 ultraviolet A light).

Block randomization led to comparable representation of keratoconus and ectasia following refractive surgery in the two treatment arms. The two one-sided test was used to assess treatment equivalence. The authors treated fellow eyes (n=207) with 5-minute dosing and considered these in the safety analysis.

The equivalent change in the topography-deprived maximum keratometry value from baseline to 6 months was the primary hypothesis. A ±0.75-dioptre margin of equivalence for the treatment difference between 2- and 5-minute dosing regimens was considered clinically relevant.

The authors also assessed adverse events and changes from baseline to 6 months in CDVA, uncorrected distance visual acuity and minimum corneal thickness.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.